The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Activity: 150 U/mg. One unit is defined as the amount of enzyme that will
phosphorylate 1 pmol of tyrosine substrate per minute at pH 7.4 and 30C. Assay buffer: 50 mM
HEPES, pH 7.4, 3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 3 uM Na-orthovanadate, 0.1 mM ATP,
30 ug/ml Poly (Glu:Tyr)4:1 substrate, and 4 ug /ml recombinant EPHB2.
Expressed in a Baculovirus infected Sf9 expression system. Expected molecular weight of 52 kDa.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Developmentally regulated EPH related tyrosine kinase
ELK related protein tyrosine kinase
Eph receptor B2
EPH tyrosine kinase 3
EPH-like kinase 5
Ephrin type B receptor 2
Ephrin type-B receptor 2
Receptor protein tyrosine kinase HEK 5
Renal carcinoma antigen NY-REN-47
Tyrosine protein kinase receptor CEK 5
Tyrosine protein kinase receptor EPH 3
Tyrosine protein kinase receptor QEK 5
Tyrosine-protein kinase receptor EPH-3
Tyrosine-protein kinase TYRO5
Receptor for members of the ephrin-B family. Phosphorylates ARHGEF15, leading to its ubiquitination and degradation by the proteasome which promotes EFNB1-dependent synapse formation. Can function in aspects of retinal ganglion cell axon guidance to the optic disk even when lacking its tyrosine kinase domain. Acts as a tumor suppressor.
Brain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain.
Involvement in disease
Defects in EPHB2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Note=EPHB2 mutations have been found in a prostate cancer cell line derived from a brain metastasis.
Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily. Contains 2 fibronectin type-III domains. Contains 1 protein kinase domain. Contains 1 SAM (sterile alpha motif) domain.